Cris Calsada
2021
In 2021, Cris Calsada earned a total compensation of $719.5K as Chief Financial Officer at Regulus Therapeutics, a 2% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $146,003 |
|---|---|
| Option Awards | $238,500 |
| Salary | $324,450 |
| Other | $10,554 |
| Total | $719,507 |
Calsada received $324.5K in salary, accounting for 45% of the total pay in 2021.
Calsada also received $146K in non-equity incentive plan, $238.5K in option awards and $10.6K in other compensation.
Rankings
In 2021, Cris Calsada's compensation ranked 9,820th out of 12,415 executives tracked by ExecPay. In other words, Calsada earned more than 20.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,820 out of 12,415 | 21st |
Division Manufacturing | 4,348 out of 5,505 | 21st |
Major group Chemicals And Allied Products | 1,936 out of 2,375 | 19th |
Industry group Drugs | 1,719 out of 2,096 | 18th |
Industry Pharmaceutical Preparations | 1,279 out of 1,546 | 17th |
Source: SEC filing on April 27, 2022.
Calsada's colleagues
We found two more compensation records of executives who worked with Cris Calsada at Regulus Therapeutics in 2021.